Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation (University of Minnesota)
- Development stage
- Unknown
- Lead developer
- Rebiotix
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Fecal microbiota transplantation (FMT) is an investigational microbial therapy being evaluated by the University of Minnesota for the treatment of pre-diabetes and metabolic syndrome. The procedure involves the transfer of distal gut microbial communities from healthy, lean donors into the gastrointestinal tract of pre-diabetic recipients, typically administered via colonoscopy. The therapeutic rationale is based on the "bioremediation" of a dysbiotic gut microbiome to improve host metabolism, specifically insulin sensitivity and glucose homeostasis. In clinical trials, FMT is often evaluated alongside antibiotic conditioning regimens (using agents such as vancomycin, neomycin, or clindamycin) designed to deplete the recipient's existing microbiota and facilitate the successful engraftment of donor-derived beneficial bacteria.
- Other names
- FMTfecal microbiota transplantInterventional Bioremediation of Microbiota
Beyond the preview
Go deeper on fecal microbiota transplantation (University of Minnesota).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation (University of Minnesota).